Article thumbnail

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters

By Rosa S Schneiderman, Esther Shmueli, Eilon D Kirson and Yoram Palti
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA
  2. (2008). Ambudkar SV: Reversal of ABC drug transportermediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol
  3. (2008). An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci
  4. (1996). Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.
  5. (2008). C: A pilot study with very lowintensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie
  6. (2003). Cabral F: Mutations in alpha- and betatubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther
  7. (2009). Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys
  8. (2006). Cucullo L: Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells.
  9. (2008). Direct current electrical fields induce apoptosis in oral mucosa cancer cells by NADPH oxidase-derived reactive oxygen species. Bioelectromagnetics
  10. (2005). Gene expression profiling in chemoresistant variants of three cell lines of different origin. Anticancer Res
  11. (2002). Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
  12. (2005). Lamph WW: The selective retinoid × receptor agonist bexarotene (LGD1069, Targetin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther
  13. (2003). MM: Pglycoprotein: from genomics to mechanism. Oncogene
  14. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer
  15. (1997). Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol
  16. (2006). Multidrug resistance: retrospect and prospects in anticancer drug treatment. Curr Med Chem
  17. (2009). Palti Y: Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis
  18. (2004). Palti Y: Disruption of cancer cell replication by alternating electric fields. Cancer Res
  19. (2008). Parissenti AM: Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
  20. (1987). Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues.
  21. (1984). Talalay P: Quantitative analysis of dose effect relationship: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul
  22. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev
  23. (2005). Uhrík B: P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets